Cellular Mechanism for Mibefradil-Induced Vasodilation of Renal Microcirculation: Studies in the Isolated Perfused Hydronephrotic Kidney

Koichi Hayashi, Yuri Ozawa, Shu Wakino, Takeshi Kanda, Koichiro Honma, Ichiro Takamatsu, Satoru Tatematsu, Takao Saruta

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Although nifedipine and other conventional calcium antagonists elicit preferential vasodilation of renal afferent arterioles, we demonstrate that mibefradil and nickel, T-type calcium channel blockers, reverse the angiotensin II-induced constriction of both afferent and efferent arterioles. Since the angiotensin II-induced vasoconstriction involves inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum in the afferent arteriole, and both IP3- and protein kinase C (PKC)-mediated pathways in the efferent arteriole, we investigated the cellular mechanism for the mibefradil-induced dilation of angiotensin II-constricted renal arterioles, using the isolated perfused hydronephrotic rat kidney. Mibefradil caused a dose-dependent dilation of angiotensin II-constricted afferent and efferent arterioles, with 88 ± 9% and 74 ± 10% reversal observed at 1 μmol/L, respectively. The blockade of PKC by staurosporine did not alter the mibefradil-induced vasodilator responses of either arterioles (P > 0.5). In contrast, the pretreatment with thapsigargin, which predominantly blocked the IP3-mediated intracellular calcium release, prevented the afferent arteriolar constrictor response to angiotensin II, but caused a significant constriction of efferent arterioles. The subsequent addition of mibefradil had no effect on the efferent arteriolar diameter. Furthermore, the efferent arteriolar constriction induced by direct PKC activation by phorbol myristate acetate was refractory to mibefradil, but completely reversed by LOE908, a nonselective cation channel blocker. In summary, mibefradil markedly dilates the angiotensin II-induced renal arteriolar constriction; the action of mibefradil is most likely mediated by the inhibition of the IP3-mediated pathway, but the inhibitory action on the PKC pathway appears modest.

Original languageEnglish
Pages (from-to)697-702
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume42
Issue number6
DOIs
Publication statusPublished - 2003 Dec

Fingerprint

Mibefradil
Arterioles
Microcirculation
Vasodilation
Angiotensin II
Kidney
Constriction
Protein Kinase C
Calcium
Dilatation
T-Type Calcium Channels
Efferent Pathways
Thapsigargin
Staurosporine
Calcium Channel Blockers
Sarcoplasmic Reticulum
Tetradecanoylphorbol Acetate
Inositol
Nifedipine
Vasoconstriction

Keywords

  • Afferent arteriole
  • Calcium antagonists
  • Efferent arteriole
  • Inositol trisphosphate
  • Mibefradil
  • T-type calcium channel

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Cellular Mechanism for Mibefradil-Induced Vasodilation of Renal Microcirculation : Studies in the Isolated Perfused Hydronephrotic Kidney. / Hayashi, Koichi; Ozawa, Yuri; Wakino, Shu; Kanda, Takeshi; Honma, Koichiro; Takamatsu, Ichiro; Tatematsu, Satoru; Saruta, Takao.

In: Journal of Cardiovascular Pharmacology, Vol. 42, No. 6, 12.2003, p. 697-702.

Research output: Contribution to journalArticle

@article{fb43f0edd5a644058ce1f1a869d21867,
title = "Cellular Mechanism for Mibefradil-Induced Vasodilation of Renal Microcirculation: Studies in the Isolated Perfused Hydronephrotic Kidney",
abstract = "Although nifedipine and other conventional calcium antagonists elicit preferential vasodilation of renal afferent arterioles, we demonstrate that mibefradil and nickel, T-type calcium channel blockers, reverse the angiotensin II-induced constriction of both afferent and efferent arterioles. Since the angiotensin II-induced vasoconstriction involves inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum in the afferent arteriole, and both IP3- and protein kinase C (PKC)-mediated pathways in the efferent arteriole, we investigated the cellular mechanism for the mibefradil-induced dilation of angiotensin II-constricted renal arterioles, using the isolated perfused hydronephrotic rat kidney. Mibefradil caused a dose-dependent dilation of angiotensin II-constricted afferent and efferent arterioles, with 88 ± 9{\%} and 74 ± 10{\%} reversal observed at 1 μmol/L, respectively. The blockade of PKC by staurosporine did not alter the mibefradil-induced vasodilator responses of either arterioles (P > 0.5). In contrast, the pretreatment with thapsigargin, which predominantly blocked the IP3-mediated intracellular calcium release, prevented the afferent arteriolar constrictor response to angiotensin II, but caused a significant constriction of efferent arterioles. The subsequent addition of mibefradil had no effect on the efferent arteriolar diameter. Furthermore, the efferent arteriolar constriction induced by direct PKC activation by phorbol myristate acetate was refractory to mibefradil, but completely reversed by LOE908, a nonselective cation channel blocker. In summary, mibefradil markedly dilates the angiotensin II-induced renal arteriolar constriction; the action of mibefradil is most likely mediated by the inhibition of the IP3-mediated pathway, but the inhibitory action on the PKC pathway appears modest.",
keywords = "Afferent arteriole, Calcium antagonists, Efferent arteriole, Inositol trisphosphate, Mibefradil, T-type calcium channel",
author = "Koichi Hayashi and Yuri Ozawa and Shu Wakino and Takeshi Kanda and Koichiro Honma and Ichiro Takamatsu and Satoru Tatematsu and Takao Saruta",
year = "2003",
month = "12",
doi = "10.1097/00005344-200312000-00001",
language = "English",
volume = "42",
pages = "697--702",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cellular Mechanism for Mibefradil-Induced Vasodilation of Renal Microcirculation

T2 - Studies in the Isolated Perfused Hydronephrotic Kidney

AU - Hayashi, Koichi

AU - Ozawa, Yuri

AU - Wakino, Shu

AU - Kanda, Takeshi

AU - Honma, Koichiro

AU - Takamatsu, Ichiro

AU - Tatematsu, Satoru

AU - Saruta, Takao

PY - 2003/12

Y1 - 2003/12

N2 - Although nifedipine and other conventional calcium antagonists elicit preferential vasodilation of renal afferent arterioles, we demonstrate that mibefradil and nickel, T-type calcium channel blockers, reverse the angiotensin II-induced constriction of both afferent and efferent arterioles. Since the angiotensin II-induced vasoconstriction involves inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum in the afferent arteriole, and both IP3- and protein kinase C (PKC)-mediated pathways in the efferent arteriole, we investigated the cellular mechanism for the mibefradil-induced dilation of angiotensin II-constricted renal arterioles, using the isolated perfused hydronephrotic rat kidney. Mibefradil caused a dose-dependent dilation of angiotensin II-constricted afferent and efferent arterioles, with 88 ± 9% and 74 ± 10% reversal observed at 1 μmol/L, respectively. The blockade of PKC by staurosporine did not alter the mibefradil-induced vasodilator responses of either arterioles (P > 0.5). In contrast, the pretreatment with thapsigargin, which predominantly blocked the IP3-mediated intracellular calcium release, prevented the afferent arteriolar constrictor response to angiotensin II, but caused a significant constriction of efferent arterioles. The subsequent addition of mibefradil had no effect on the efferent arteriolar diameter. Furthermore, the efferent arteriolar constriction induced by direct PKC activation by phorbol myristate acetate was refractory to mibefradil, but completely reversed by LOE908, a nonselective cation channel blocker. In summary, mibefradil markedly dilates the angiotensin II-induced renal arteriolar constriction; the action of mibefradil is most likely mediated by the inhibition of the IP3-mediated pathway, but the inhibitory action on the PKC pathway appears modest.

AB - Although nifedipine and other conventional calcium antagonists elicit preferential vasodilation of renal afferent arterioles, we demonstrate that mibefradil and nickel, T-type calcium channel blockers, reverse the angiotensin II-induced constriction of both afferent and efferent arterioles. Since the angiotensin II-induced vasoconstriction involves inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum in the afferent arteriole, and both IP3- and protein kinase C (PKC)-mediated pathways in the efferent arteriole, we investigated the cellular mechanism for the mibefradil-induced dilation of angiotensin II-constricted renal arterioles, using the isolated perfused hydronephrotic rat kidney. Mibefradil caused a dose-dependent dilation of angiotensin II-constricted afferent and efferent arterioles, with 88 ± 9% and 74 ± 10% reversal observed at 1 μmol/L, respectively. The blockade of PKC by staurosporine did not alter the mibefradil-induced vasodilator responses of either arterioles (P > 0.5). In contrast, the pretreatment with thapsigargin, which predominantly blocked the IP3-mediated intracellular calcium release, prevented the afferent arteriolar constrictor response to angiotensin II, but caused a significant constriction of efferent arterioles. The subsequent addition of mibefradil had no effect on the efferent arteriolar diameter. Furthermore, the efferent arteriolar constriction induced by direct PKC activation by phorbol myristate acetate was refractory to mibefradil, but completely reversed by LOE908, a nonselective cation channel blocker. In summary, mibefradil markedly dilates the angiotensin II-induced renal arteriolar constriction; the action of mibefradil is most likely mediated by the inhibition of the IP3-mediated pathway, but the inhibitory action on the PKC pathway appears modest.

KW - Afferent arteriole

KW - Calcium antagonists

KW - Efferent arteriole

KW - Inositol trisphosphate

KW - Mibefradil

KW - T-type calcium channel

UR - http://www.scopus.com/inward/record.url?scp=0041605128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041605128&partnerID=8YFLogxK

U2 - 10.1097/00005344-200312000-00001

DO - 10.1097/00005344-200312000-00001

M3 - Article

C2 - 14639089

AN - SCOPUS:0041605128

VL - 42

SP - 697

EP - 702

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -